Pharmacokinetic-Pharmacodynamic Correlation for Meropenem Applied to a Burn Child Using a Bioanalytical Liquid Cromatographic Method

Pharmacokinetic-Pharmacodynamic Correlation for Meropenem Applied to a Burn Child Using a Bioanalytical Liquid Cromatographic Method

Bioanalytical method for LC meropenem quantification in plasma was described. Good absolute recovery (higher than 90%), adequate linearity (0.2-50.0 μg/mL, r2=0.999), high sensitivity (LOQ: 0.2 μg/mL; LOD: 0.1μg/mL) and acceptable stability were shown. Interday/intraday precisions were 2.3%/2.0% and...

Full description

Bibliographic Details
Main Authors:	Silvia R. C. J. Santos, Cristina Sanches-Giraud, Carlindo Vieira Jr., Flávio F. de Souza, David S. Gómez, Edvaldo V. Campos, Rodrigo P. de Azevedo, Marcus C. Ferreira, Jorge W. L. Nascimento
Format:	Article
Language:	English
Published:	Formifarma, LDA. 2011-10-01
Series:	Revista Portuguesa de Farmacoterapia
Subjects:	Meropenem LC burn child drug plasma monitoring pharmacokinetics-pharmacodinamics correlation
Online Access:	http://revista.farmacoterapia.pt/index.php/rpf/article/view/79

Similar Items

Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: Are we getting close to the right treatment?
by: Silvia Corcione, et al.
Published: (2020-03-01)

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
by: Eric Wenzler, et al.
Published: (2020-10-01)

Is Meropenem as a Monotherapy Truly Incompetent for Meropenem-Nonsusceptible Bacterial Strains? A Pharmacokinetic/Pharmacodynamic Modeling With Monte Carlo Simulation
by: Xiangqing Song, et al.
Published: (2019-11-01)

Clinical Pharmacology of Meropenem in Neonates: Effects and Pharmacokinetics
by: Gian Maria Pacifici
Published: (2016-11-01)

Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients
by: Sonia Luque, et al.
Published: (2021-06-01)

Population pharmacokinetics of meropenem in critically ill infant patients
by: Wanlika Yonwises, et al.
Published: (2021-10-01)

Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study
by: Hui-Ying Zhao, et al.
Published: (2017-01-01)

The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis
by: Ahmed A. Abulfathi, et al.
Published: (2021-06-01)

Population Pharmacokinetics of Vancomycin and Meropenem in Pediatric Extracorporeal Membrane Oxygenation Support
by: Brenda Zylbersztajn, et al.
Published: (2021-08-01)

Meropenem pharmacokinetics during relapsing peritonitis due to ESBL‐producing Enterobacteriaciae in a liver transplant recipient
by: Kensuke Shoji, et al.
Published: (2019-11-01)

Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study
by: Stephan Braune, et al.
Published: (2018-01-01)

Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis
by: Renata Černá Pařízková, et al.
Published: (2021-07-01)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients Are Not Affected by Extracorporeal Membrane Oxygenation: A Matched Cohort Analysis
by: Matthias Gijsen, et al.
Published: (2021-06-01)

Evaluation of Meropenem Pharmacokinetics in an Experimental Acute Respiratory Distress Syndrome (ARDS) Model during Extracorporeal Membrane Oxygenation (ECMO) by Using a PenP β-Lactamase Biosensor
by: Max Andresen, et al.
Published: (2018-05-01)

Computerized techniques pave the way for drug-drug interaction prediction and interpretation
by: Reza Safdari, et al.
Published: (2016-06-01)

Meropenem pharmacokinetics during extracorporeal membrane oxygenation and continuous haemodialysis: a case report
by: Jumpei Saito, et al.
Published: (2020-09-01)

Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and <i>P. aeruginosa</i>
by: Pier Giorgio Cojutti, et al.
Published: (2020-08-01)

Meropenem Plasma and Interstitial Soft Tissue Concentrations in Obese and Nonobese Patients—A Controlled Clinical Trial
by: Philipp Simon, et al.
Published: (2020-12-01)

Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: implications for empirical therapy against Gram-negative bacteria
by: Amol T. Kothekar, et al.
Published: (2020-01-01)

Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial
by: Adela Benítez-Cano, et al.
Published: (2020-02-01)

Pharmacokinetic-pharmacodynamic correlation of imipenem in pediatric burn patients using a bioanalytical liquid chromatographic method
by: Silvia Regina Cavani Jorge Santos, et al.
Published: (2015-06-01)

The Role of Non-Enzymatic Degradation of Meropenem—Insights from the Bottle to the Body
by: Uwe Liebchen, et al.
Published: (2021-06-01)

Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing <i>K. pneumoniae</i> Septic Thrombosis Unresponsive to Ceftazidime/Avibactam: From the Bench to the Bedside
by: Alessandra Oliva, et al.
Published: (2021-06-01)

Appropriate Use of Meropenem: A Pharmacy Intervention
by: Stacey Abbott, et al.
Published: (2014)

Pharmacokinetic and Pharmacodynamic Modeling of Antibiotics and Bacterial Drug Resistance
by: Syed Mohamed, Ami Fazlin
Published: (2013)

Meropenem: A possible new culprit in eosinophilic lung diseases
by: Nathalie Abi Hatem, et al.
Published: (2017-01-01)

Meropenem Induced Skin Drug Eruption in Infectious Mononucleosis: Immunological Phenomena or Non-immunological Phenomena?
by: Atousa Hakamifard, et al.
Published: (2020-01-01)

Optimized Dosing Regimens of Meropenem in Septic Children Receiving Extracorporeal Life Support
by: Yixue Wang, et al.
Published: (2021-08-01)

Combined Use of Vancomycin and Meropenem in Patient with Acute Intermittent Porphyria: A Case Report
by: İrfan ŞENCAN, et al.
Published: (2004-09-01)

Treatment of nosocomial pneumonia: an experience with meropenem
by: Santos Sigrid S., et al.
Published: (2001-01-01)

Treatment of nosocomial pneumonia: an experience with meropenem
by: Sigrid S. Santos, et al.

Removal of Meropenem by using Lemna minor
by: Noora Saad, et al.
Published: (2021-10-01)

Meropenem Stability in Human Plasma at −20 °C: Detailed Assessment of Degradation
by: Matthias Gijsen, et al.
Published: (2021-04-01)

The In vitro Activity of Meropenem to Nosocomial Pseudomonas aeruginosa Isolates
by: Mustafa ÖZYURT, et al.
Published: (1998-09-01)

Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness—Experience and Recommendations from One Year in Routine Clinical Practice
by: Christina Scharf, et al.
Published: (2020-03-01)

The Appropriateness of Antibiotic Therapy in Patients Initiated on Meropenem in a University-Affiliated Hospital
by: Wolken, Kathryn, et al.
Published: (2011)

Modelagem PK/PD na terapia antimicrobiana com carbapenêmico em pacientes sépticos críticos grandes queimados. \"Estudo da efetividade do meropenem administrado através de infusão intermitente versus estendida\"
by: Kupa, Leonard de Vinci Kanda
Published: (2019)

Meropenem utilization evaluation in a referral teaching hospital in Iran
by: Peyman Naderi, et al.
Published: (2018-01-01)

In vitro activity of meropenem, imipenem, cefepime, cefoxitin and ciprofloxacin against multiresistant Klebsiella pneumoniae.
by: P Pruekprasert, et al.
Published: (2006-06-01)

Evolución clínica de la endocarditis infecciosa en pacientes tratados con Meropenem
by: Mariam Gonzalez Gorrin, et al.
Published: (2020-09-01)

Cannot write session to /tmp/vufind_sessions/sess_d15r9rji2sf5thelc4ojprn99i